Waleed Abdelmaguid

Skilled Researcher enthusiastic about supporting advancements in molecular and cellular biology. Passionate about increasing knowledge to drive growth and needed improvements. Ready to apply knowledge and over 20 years of experience.

• American Society of Gene and Cell Therapy (Bio-Industry Committee Member)
• European Organ on Chip Society
• COVID-19 HLA and Immunogenetics Consortium Member

• KIR genotypes impact progression to hepatocellular carcinoma in patients with chronic hepatitis C infection, International Liver cancer Association (ILCA) 17th annual conference, 7-9th September 2023, Amsterdam, The Netherlands, Poster presentation
• Exploratory Analysis Of KIR Genotypic Structure In Egyptians And Caucasian Americans With Hepatitis C Virus-Associated Hepatocellular Carcinoma, Hepatology on the Nile 2 congress, Sept 24-25, 2014, Cairo, Egypt, Poster presentation

• CGMP: Quality Assurance and Quality Control Training course (Biopharma Institute)
• Good Clinical Practice (USA FDA focus) Basic Training Course, Certification 46111375
• NIH Online Training Course "Protecting Human Research Participants", Certification 119705
• International Computer License (ICDL) version 4, Certification EGY000113490

• Invited reviewer for the 2022 grant on the project "Novel brainstem delivery AAV-based gene therapy for sensorineural hearing loss", Department of Neurological Surgery, The Ohio State University Wexner Medical Center.
• Invited Judge for 12 posters in 2022 Symposium, Neurosciences Research Institute, The Ohio State University.
• Editor Reviewer Board Member (Journal of American Academic Research).
• Editor Reviewer Board Member (Journal of Molecular Biomedical Research).

• KIR genotypes impact progression to hepatocellular carcinoma in patients with chronic hepatitis C infection, Abdelmaguid W, Maher D, Kohla M.A.S, Ezzat S, Moaz, Wael. Abdel-Mageed W.S, El-Halfawy K.A, Abdel-Rahman M.H., Livers, 3, 354-368, 2023, https://doi.org/10.3390/livers3030027
• Low frequency of aflatoxin induced TP53 gene codon 249 mutation in hepatocellular carcinoma from Egyptian patients living in the Nile Delta resion, Mosbeh A, Abdelmaguid W, Ezzat S, Kohla M.A.S, Sultan M.M, Abdel-Rahman M.H., Asian Pac J Cancer Prev, 24 (9), 3165-3168, 2023, DOI:10.31557/APJCP.2023.24.9.3165

• At Dr. Meyer lab at Nationwide Children's Hospital, 2021-present, USA, Spearheaded innovative, employing animal (Mice, Non-Human Primates) and in vitro disease models to drive IND-enabling studies focused on rare neurological seizure disorders; obtained critical insights into disease mechanisms and efficacy of novel therapeutic approaches. Planned the development and implementation of a robust molecular biology and cell culture protocol, resulting in the successful generation of AAV9 vector constructs; instrumental in advancing cutting-edge research towards potential therapeutic breakthroughs. Developed and implemented cutting-edge techniques in in vitro cellular reprogramming, resulting in a 60% improvement in research productivity. Mastered and optimized stem cell culture techniques, implementing a co-culture system and generating EB cells, resulting in a 40% increase in cell viability and enhanced research accuracy.
• At Dr. Abdel-Rahman Lab, The Ohio State University 2018-2021, USA, Led an innovative research initiative at Ophthalmology department, delving into the intricate molecular interplay between the BAP1 gene and variant in HERC2/OCA2 gene. Pioneered the development of an innovative in vitro 3D cell culture model for angiogenesis, resulting in a 20% increase in research efficiency and enabling precise evaluation of anti-angiogenic compounds for potential therapeutic applications. Streamlined the application of cutting-edge techniques to establish and maintain primary melanocyte cultures from human eye donors, resulting in groundbreaking scientific discoveries and fueling the progress of research initiatives. Conducted research on uveal and skin cancer cell lines, employing advanced techniques to analyze behavior and treatment response; contributed to the development of targeted therapies resulting in a 25% increase in treatment efficacy. Created a highly innovative rodent melanoma model by introducing mutant OCA2 on the mutant BAP1 gene background, enabling in-depth analysis of both primary and metastatic tumors. Executed precision CRISPR gene knockout experiments targeting the BAP1 gene, resulting in the identification of novel phenotypic changes and contributing to a deeper understanding of the impact on cellular function and disease progression.
• Internship at Dr. Cooper's Lab, California Pacific Medical Center 2014, USA, Orchestrated the successful implementation of KIR/HLA SSP-PCR genotyping, blood processing, bio-banking, and cell culturing protocols; unveiled groundbreaking genetic markers with significant clinical potential, revolutionizing research outcomes. Led and initiated a cutting-edge pilot study examining the diversity of KIR genotypes in HCV-related HCC patients from Egypt and American Caucasians; uncovered unique genetic patterns that hold tremendous potential for precision medicine interventions, paving the way for personalized treatment strategies. Presented a groundbreaking research poster at the prestigious International Conference of Hepatology on the Nile 2 in 2014 in Cairo, Egypt.
• At Sustainable Sciences Institute Collaborative Research Center 2011-2018, Egypt, Developed standardized operating procedures (SOPs) and best practices for a groundbreaking HCC bio-bank and collaborative clinical research center, resulting in streamlined operations, enhanced data management, and increased research output by 50%. Initiated and steered a cutting-edge research study analyzing the complete KIR profile in HCV-associated HCC patients in Egypt; generated invaluable insights into disease progression and identified promising therapeutic targets, with the potential to transform patient outcomes.

Honored Listee in Marquis Who's Who in America. 2023.